Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy
Autor: | Yen-Yang Chen, Pei-Hung Chang, Shun-Wen Hsueh, Pei-Wei Huang, Yu-Shin Hung, Kun-Yun Yeh, Wen-Chi Chou, Jen-Shi Chen, Chang-Hsien Lu, Chia-Yen Hung, Ching-Fu Chang |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
Oncology Male Cancer Research medicine.medical_treatment pancreatic cancer Deoxycytidine 0302 clinical medicine Antineoplastic Combined Chemotherapy Protocols Medicine prognostic model Original Research Aged 80 and over Hazard ratio Palliative Care palliative chemotherapy Middle Aged lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Prognosis Drug Combinations Treatment Outcome 030220 oncology & carcinogenesis Female medicine.drug medicine.medical_specialty Combination therapy lcsh:RC254-282 03 medical and health sciences Young Adult Internal medicine Pancreatic cancer Humans Radiology Nuclear Medicine and imaging Aged Proportional Hazards Models Retrospective Studies Tegafur Chemotherapy business.industry Clinical Cancer Research Palliative chemotherapy Models Theoretical medicine.disease Survival Analysis Gemcitabine Confidence interval Pancreatic Neoplasms Regimen Oxonic Acid 030104 developmental biology business |
Zdroj: | Cancer Medicine Cancer Medicine, Vol 8, Iss 12, Pp 5554-5563 (2019) |
ISSN: | 2045-7634 |
Popis: | Background We previously developed a robust prognostic model (GS model) to predict the survival outcome of patients with advanced pancreatic cancer (APC) receiving palliative chemotherapy with gemcitabine plus S‐1 (GS). This study aimed to validate the application of the GS model in APC patients receiving chemotherapy other than the GS regimen. Patients and methods We retrospectively analyzed 727 APC patients who received first‐line palliative chemotherapy other than the GS regimen between 2010 and 2016 at four institutions in Taiwan. The patients were categorized into three prognostic groups based on the GS model for comparisons of survival outcome, best tumor response, and in‐group survival differences with monotherapy or combination therapy. Results The median survival times for the good, intermediate, and poor prognostic groups were 13.4, 8.4, and 4.6 months, respectively. The hazard ratios for the comparisons of intermediate and poor to good prognostic groups were 1.51 (95% confidence interval [CI]), 1.22‐1.88, P This study provided validation of the previously developed gemcitabine + S‐1 model in predicting the survival outcome of advanced pancreatic cancer patients receiving first‐line palliative chemotherapy. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |